[go: up one dir, main page]

WO2006081739A1 - Composition servant à traiter ou à prévenir l'hyperlipémie, l'hypertension ou l'infiltration lipidique hépatique - Google Patents

Composition servant à traiter ou à prévenir l'hyperlipémie, l'hypertension ou l'infiltration lipidique hépatique Download PDF

Info

Publication number
WO2006081739A1
WO2006081739A1 PCT/CN2006/000083 CN2006000083W WO2006081739A1 WO 2006081739 A1 WO2006081739 A1 WO 2006081739A1 CN 2006000083 W CN2006000083 W CN 2006000083W WO 2006081739 A1 WO2006081739 A1 WO 2006081739A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
test
hypertension
composition
crataegus
Prior art date
Application number
PCT/CN2006/000083
Other languages
English (en)
Chinese (zh)
Inventor
Xinfu Guo
Original Assignee
Xinfu Guo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinfu Guo filed Critical Xinfu Guo
Publication of WO2006081739A1 publication Critical patent/WO2006081739A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • composition for treating or preventing hyperlipemia, hypertension, fatty liver Composition for treating or preventing hyperlipemia, hypertension, fatty liver
  • the present invention relates to a composition for treating or preventing dyslipidemia, hypertension, fatty liver, and use for making a medicament or a health food. Background technique
  • cardiovascular and cerebrovascular diseases have become the number one killer of human health.
  • Hyperlipidemia characterized by elevated LDL and very low-density lipoprotein is one of the major risk factors for atherosclerosis and coronary heart disease.
  • it may be complicated by myocardial ischemia, angina pectoris, etc.
  • a series of cardiovascular diseases At present, there are many kinds of drugs for preventing and treating dyslipidemia in the world, among which HMG-CoA reductase inhibitors (statins) are the most effective blood lipid regulating drugs, and have obvious curative effects in treating severe phlegmemia.
  • statins HMG-CoA reductase inhibitors
  • the side effects of chemical drugs make it difficult for patients with moderate or mild hyperlipidemia to take it for a long time.
  • Fatty liver is caused by a large accumulation of fat in the liver, and its incidence rate is as high as 10-20%. About 35% of patients with elevated transaminase in adult physical examination are fatty liver, and some patients can develop cirrhosis. Fatty liver is often associated with increased blood lipids. Foreign researchers have also found that patients with arterial hypertension are more prone to fatty liver than those with other major risk factors such as elevated liver enzymes or hepatic steatosis. On the other hand, fatty liver in overweight and obese people often suggests malignant obesity, the latter with impaired glucose tolerance, hyperlipidemia and hypertension collectively referred to as the "death quartet". These patients are highly prone to fatal heart and brain. Vascular disease.
  • the object of the present invention is to overcome the problems in the prior art, and to provide a Chinese patent medicine or a health food product having a significant effect on preventing and treating hyperlipidemia, hypertension, and fatty liver disease by using a medicine and food plant as a raw material. Compositions and their use in the preparation of such drugs or health foods.
  • Red yeast has been a good product for medicine and food since ancient times. It has the effects of digestion and promoting blood circulation, spleen and stomach. Red yeast contains
  • HMG-CoA reductase inhibitor with a mechanism of action of statins. Because it is a natural product, it is far superior to synthetic statins in terms of safety. In recent years, scholars at home and abroad have also found that red yeast has the functions of lowering fat, lowering blood pressure and lowering sugar.
  • Soy isoflavones are natural phytoestrogens that are safe and have no toxic side effects. Studies have shown that soy isoflavones can reduce the body's susceptibility to serum LDL oxidation, increase the antioxidant capacity of serum LDL, prevent the formation of atherosclerotic plaques in arterial vessels, prevent atherosclerosis, and increase arterial blood vessels. Compliance, dilation of blood vessels. Japanese researchers also found that soy isoflavones also have the effect of lowering blood pressure and preventing stroke.
  • Alisma is a commonly used traditional Chinese medicine. Clinical observations have shown that the extract of Alisma can reduce the blood triglyceride (TC) content while reducing blood TC. Single-flavored Alisma preparations have a certain effect on IIa, II b IV, V-type hyperlipoproteinemia, especially for high TC. Alisma can reduce the LDL content in the blood and increase the HDL level and the ratio of HDL-Ch to TC. For experimental atherosclerotic rabbits, Alisma orientalis extract can significantly inhibit the formation of active endometrial plaque. Alisma has a mild blood pressure lowering effect.
  • Alisma extract and zebra alcohol have a relaxing effect on the excision-free aortic strip contraction, which inhibits the influx of calcium-voltage-dependent calcium channels. Selective diarrhea also improves liver fat metabolism and has an anti-fatty liver effect.
  • the water extract of Alisma orientale or benzene extract can reduce the fat content in the liver and protect the liver damage caused by CCL4.
  • Hawthorn has the effect of promoting blood circulation and removing blood stasis. It is a traditional medicine that promotes digestion and eliminates greasy meat and food. Modern pharmacological studies have proved that hawthorn can lower blood fat, reduce blood pressure, resist atherosclerosis, increase coronary blood flow, improve coronary circulation, and make coronary artery failure compensate, achieve cardiotonic effect, and improve The sensitivity of the myocardium to cardiac palpitations, increased cardiac output, reduced myocardial stress and conductivity, anti-ventricular fibrillation, atrial fibrillation and paroxysmal arrhythmia, and restore the heart's pulsation.
  • Cassia is a seed of the legumes Cassia Cassia or Cassia. It contains decyl esters and guanidines, cassia and vitamin A. Pharmacological tests prove that Cassia has the effect of lowering blood pressure and lowering serum cholesterol. The role of pathogenic bacteria and soft stools. Chinese medicine believes that its sexuality is slightly cold, sweet, bitter, functional, clearing the liver and improving eyesight, benefiting water and laxative, suitable for liver heat or liver heat caused by wind and heat, shame and tears, etc.; , hepatitis, cirrhosis ascites and habitual constipation are also effective.
  • the present invention provides a composition for treating or preventing hyperlipemia, sputum blood pressure, fatty liver, which is characterized by being prepared from a drug substance having the following weight ratio: 5-60 parts of red yeast rice, soybean different 0.3-50 parts of flavonoids and 10-75 parts of Alisma.
  • the composition of the present invention is prepared from a raw material having the following weight ratio. Ingredients: 5-35 parts of red yeast rice, 1-30 parts of soy isoflavones, 20-70 parts of Alisma.
  • the composition of the present invention is prepared from a drug substance having a weight ratio of 10-25 parts of red yeast, 2-10 parts of soy isoflavones, and 30-60 parts of Alisma.
  • the starting material of the composition of the present invention further comprises 10 to 60 parts by weight, preferably 20 to 40 parts, more preferably 20 to 30 parts, and most preferably 25 parts by weight of hawthorn.
  • the raw material of the composition of the present invention further comprises 5 to 60 parts by weight, preferably 10 to 40 parts, more preferably 10 to 20 parts, and most preferably 15 parts by weight of cassia seed.
  • the composition of the present invention comprises the following weight ratio of the original drug: 12 parts of red yeast rice, 4 parts of soy isoflavones, 38 parts of Alisma, 28 parts of Hawthorn, Cassia 18 Share.
  • the composition of the present invention is in the form of a solid preparation, preferably a tablet, a capsule, a granule or a granule.
  • the invention also provides the use of the composition for the manufacture of a medicament for the treatment or prevention of noxious, hypertensive, fatty liver.
  • the invention also provides the use of the composition for the preparation of a health food for the treatment or prevention of hyperlipidemia, 'sputum blood pressure, fatty liver.
  • the ratios referred to in this patent application are all by weight or by weight unless otherwise stated.
  • the preparation method of the present invention is as follows: The Alisma orientalis, Hawthorn, Cassia seed (or Alisma orientale and Hawthorn; or Alisma orientale) are formulated according to the formula ratio, and water is extracted twice, each time adding water 10 times, boiling for 1.5 hours, and filtering. The filtrate was combined; the filtrate was concentrated under reduced pressure to obtain a concentrated liquid; the concentrate was added with 95% ethanol to form an alcohol content of 50%, and the alcohol was precipitated for 24 hours, and filtered to obtain an alcohol filtrate; the alcohol filtrate was concentrated to a thick paste.
  • the finished product may be in the form of tablets or capsules or granules or granules.
  • the recommended amount of the composition of the present invention is 2.0 g/person/day for tablets and capsules, 4.0 g/person/day for granules and granules, orally administered twice, depending on the dosage form, swallowed or blunt with water.
  • composition of the invention has no toxic and side effects, has good lipid-lowering effect, can significantly lower blood cholesterol, triglyceride and low density lipoprotein, and has obvious effects on preventing and treating hypertension and fatty liver, and can be used for preparing and preventing hyperlipidemia. Hypertension, fatty liver drugs or health foods.
  • Example 1 0.5 g/tablet tablets were weighed according to the weight ratios described in the following table:
  • Example 2 0.5 g/granule capsule formula 1 Formulation 2 Formulation 3 Formulation 4 Ingredient I Weight ratio Raw material drug weight ratio Raw material drug weight ratio Raw material drug weight ratio Raw material drug Red yeast 9.0 250g 11.8 250 10.9 250g 21.7 250g Soy isoflavones 1.5 40g 3.3 70 1.7 40g 8.7 100g Alisma 35.8 1000g 37.7 800 43.7 1000g 69.6 800g Hawthorn 35.8 1000g 28.3 600 43.7 1000g - Cassia 17.9 500g 18.9 400 - Will be diarrhea, hawthorn, cassia seed (or Alismaea and hawthorn; Or Alisma) Ingredients according to the formula, add water for 2 times, add 10 times of water each time, boil for 1.5 hours, filter, and combine the filtrate; concentrate the filtrate under reduced pressure to obtain a concentrated liquid; concentrate with 95% ethanol to form alcohol content After 50%, the alcohol was precipitated for 24 hours, and filtered to obtain an alcohol filtrate; the alcohol filtrate was concentrated to
  • red yeast rice and soybean isoflavones can be added, and appropriate amount of auxiliary materials (dextrin or vertical collapse) can be added to mix and granulate.
  • auxiliary materials dry, whole grained dry granules, filled into capsules, that is, 1000 capsules, 0.5g / granules.
  • Example 3 2 g / bag of granules
  • the alcohol filtrate was obtained by filtration; the alcohol filtrate was concentrated to a thick paste.
  • Add red yeast rice, soy isoflavones according to the proportion of the formula add appropriate amount of auxiliary materials (sucrose or dextrin), mix, granulate, dry, whole grain to obtain dry granules, and package, that is, granules 1000 packs, 2g/bag.
  • Weight ratio drug substance, weight ratio, drug substance, weight ratio, drug substance, weight ratio, drug substance, weight ratio, drug substance, weight ratio, drug substance, weight ratio, drug substance, weight ratio, drug substance
  • Test substance The capsules produced according to the formula (1) of the present invention, which are referred to as the test materials, are provided by Hangzhou Xinfu Pharmaceutical Co., Ltd.
  • Test animals ICR mice, clean grade; SD rats, clean grade. Provided by Zhejiang Experimental Animal Center, Medical Laboratory Animal Qualification Certificate 2001001.
  • Rats weigh 180-220 g, 20 males and 20 females; ICR mice weigh 18-22 g, 20 males and 20 females.
  • SD rats and ICR mice were randomly divided into four dose groups of 1.00 g/kg, 2.15 g/kg, 4.64 g/kg, and 10.00 g/kg body weight according to Horn's method, with 5 males and 5 females in each group. After 6 hours, the animals in each group were given the test substance once a day, and the general condition, poisoning symptoms and death of the rats and mice were observed to determine the half-lethal death of the test article on rats and mice. The dose was LD 5Q and the observation period was 2 weeks. The results are shown in Table 1. Table 1 Acute toxicity of test substances to rats and mice
  • mice weigh 25-28g. Mice were randomly divided into three dose groups of 2.5, 5.0, 10.0 g/kg body weight, one negative control group (1% carboxymethylcellulose) and one positive control group (cyclophosphamide 40 mg/kg body weight), 10 rats in each group. 5 males and 5 females. The test substance was formulated into a corresponding dose with 1% carboxymethylcellulose. The mice were intragastrically administered twice a day for 24 hours, and were sacrificed after 6 hours of the second gavage. Bone marrow was prepared from bone marrow, fixed in methanol, and stained with Giemsa. At the time of microscopic examination, 1000 polychromatic red blood cells were counted per animal, and the micronucleus was calculated. The results are shown in Table 4. Table 4 Effect of test substance on micronucleus rate in mice
  • mice 50 ICR male mice, weighing 21-25g. Three dose groups of 2.5, 5.0, 10.0 g/kg body weight, one negative X-inch group (1% carboxymethylcellulose) and one positive control group (Mitomycin C 2.0 mg/kg body weight), each group 10 only. The samples were administered by gavage for 5 consecutive days, once a day, and the control group was treated the same. After the first 35 days after the first infusion, the rats were sacrificed by dislocation. Five mice in each group were randomly selected from the epididymis, and directly smeared as a leachate. They were naturally dried, fixed in methanol, and stained with 1% eosin. Sperm morphology was observed and counted under high magnification. Each mouse counted 1000 intact spermatozoa and the incidence of sperm abnormality (%) was calculated. The results are shown in Table 5. Effect of test substance on the incidence of sperm abnormality in mice
  • SD rats were randomly divided into 4 groups, 20 in each group, half male and half female.
  • the test was set as a control group, and the test subjects were reconstituted at 1.25, 2.5, and 3.3 g/kg.
  • the test substance is administered by means of incorporation into a feed. Eat freely, drink water, record weight and food intake weekly and calculate food utilization. At the end of the experiment period, fasting was performed overnight, and the next day, the rats were killed by decapitation. Organs were weighed and examined for liver and kidney pathology in the control group and the sputum dose group. Blood samples were taken for blood and blood biochemistry. The experimental results are shown in Table 6, Table 7, Table 8, Table 9, and Table 10.
  • Sex Dose (g/kg) Number of Rats Liver Ratio (%) Renal to Body Ratio (%) Spleen Ratio (%) Tester Ratio (%) Female 0.0 10 3.43 ⁇ 0.15 0.90 ⁇ 0.08 0.26+ 0.02
  • the composition of the present invention has an oral LDso of more than 10.00 g kg body weight in both male and female mice, and is practically non-toxic.
  • the Ames test, mouse bone marrow micronucleus test, and mouse sperm abnormality test results were all negative.
  • the results of 30-day feeding test in rats showed no symptoms of poisoning in experimental animals, no abnormal pathological changes in gross anatomy, and no damaging effects on blood routine and biochemical indicators.
  • Sample A tablet produced according to the formula (1) of the present invention, which is hereinafter referred to as a test substance; a placebo (starch), provided by Hangzhou Xinfu Pharmaceutical Co., Ltd., both in packaging, appearance, The color and taste are exactly the same, and the recommended intake is 2.0g/day.
  • Subject selection Patients with hyperlipidemia aged 18-65 years old, required to maintain a normal diet, blood collection 2 times within half a year, serum total cholesterol (TC) 5.2mmol L or serum triglyceride (TG) ⁇ 1.65mmol L can be included in the trial.
  • TC total cholesterol
  • TG serum triglyceride
  • Test methods Double-blind random grouping, two groups of control designs. According to the above criteria, 100 patients with hyperlipidemia were selected, including 25 patients with hypertension and 18 patients with fatty liver. According to age, sex, blood lipid level, etc., they were randomly divided into two groups: the test group and the control group, of which 50 were in the test group. 50 cases. The test group took the test substance twice a day, 2 tablets each time, and the control group took a placebo, taking the same method as the test group for 30 days.
  • Safety indicators blood, urine, stool routine examination, including blood red blood cell count (RBC), hemoglobin (Hb), white blood cell count (WBC); biochemical indicators, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum total Protein (TP), albumin (ALB), blood glucose (GLU;), urea nitrogen (BIM), creatinine (Cr); electrocardiogram; abdominal B-ultrasound; X-ray chest fluoroscopy. ⁇
  • Efficacy index Blood intake on fasting, determination of serum total cholesterol (TC:), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) levels and percentage reduction, high-density lipoprotein cholesterol (HDL-C) Level and extent of increase.
  • TC serum total cholesterol
  • TG triglyceride
  • LDL-C low-density lipoprotein cholesterol
  • HDL-C high-density lipoprotein cholesterol
  • Test group 50 37 13 . 74.00 P 0.000
  • Control group 50 1 ⁇ 55 ⁇ 0 ⁇ 25 1.50 ⁇ 0.20 0.953 ⁇ 0.21 1.738 0.088 Test group 50 1.53 +0.44 1.52 ⁇ 0.41 0.007 + 0.27 0.185 0.854 t ' 0.292 0.944 3
  • Low-density lipoprotein cholesterol The changes of low-density lipoprotein cholesterol before and after the test are shown in Table 15. Table 15 shows that the difference in low-density lipoprotein cholesterol after the test group was significantly higher than that before the test (P ⁇ 0.01), and the difference was significant compared with the control group (P ⁇ 0.05). Changes in low-density lipoprotein cholesterol before and after the two groups (m'mol/L, x ⁇ SD)
  • Control group 50 3.18 ⁇ 0.58 3.11 ⁇ 0.74 0.08 ⁇ 0.40
  • Test group 50 3.24 + 0.65 2.83 ⁇ 0.50* # 0.41 ⁇ 0.52
  • composition of the present invention can lower serum total cholesterol and triglyceride levels, and the comparison between the test group and the two groups is significant ( ⁇ 0.05), wherein the total cholesterol decreases.
  • the triglyceride decreased by an average of 25.05%, and the high-density lipoprotein cholesterol level did not decrease significantly compared with the control group.
  • the total effective rate was 74%, which was significantly different from the control group (28%) ( ⁇ 0.01).
  • 25 patients with hypertension, after taking the drug 21 patients with significantly lower blood pressure; 18 patients with fatty liver, through the film control, 11 months after medication, 11 patients with significantly reduced fibrosis .
  • the composition of the present invention has no toxic and side effects, has a significant blood lipid regulating effect, and has obvious effects on preventing and treating hypertension and fatty liver, and can be used for long-term use in patients with hyperlipidemia, hypertension, and fatty liver. Drug or health food.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Composition servant à traiter ou à prévenir l'hyperlipémie, l'hypertension et l'infiltration lipidique hépatique. La composition est préparée en utilisant les proportion en poids de médicaments matières premières suivantes : 5-60 parties de Monascus purpureus Went, 0,3-50 parties d'isoflavone de soja, 10-75 parties de rhizome de Alisma plantago-aquatica L. var. Orientale Samuels, ainsi que facultativement l'un du fruit de Crataegus pinnatifida Bge. var. Major N. E. Br., de Crataegus cuneata Sieb. Et Zucc., de Crataegus pinnatifida, de Crataegus hupensis Sarg., de Crataegus Pall., de Crataegus scabrifolia (Franch.) Rehd. ou de la semence de Cassia tora L. ou les deux. La composition selon la présente invention n'a pas d'effet secondaire toxique et présente de bons effets sur la régulation de la graisse, elle peut réduire de façon significative le taux sanguin de cholestérol, de triglycérides et de lipoprotéines de faible densité, elle a des effets visibles sur le traitement et la prévention de l'hypertension, de l'infiltration lipidique hépatique et elle peut être utilisée dans la préparation de médicaments ou d'aliments diététiques servant à traiter et à prévenir l'hyperlipémie, l'hypertension et l'infiltration lipidique hépatique.
PCT/CN2006/000083 2005-02-06 2006-01-19 Composition servant à traiter ou à prévenir l'hyperlipémie, l'hypertension ou l'infiltration lipidique hépatique WO2006081739A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200520049103.8 2005-02-06
CN200520049103 2005-02-06

Publications (1)

Publication Number Publication Date
WO2006081739A1 true WO2006081739A1 (fr) 2006-08-10

Family

ID=36776950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/000083 WO2006081739A1 (fr) 2005-02-06 2006-01-19 Composition servant à traiter ou à prévenir l'hyperlipémie, l'hypertension ou l'infiltration lipidique hépatique

Country Status (1)

Country Link
WO (1) WO2006081739A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526276A (zh) * 2012-01-11 2012-07-04 张继述 一种降压药物组合物及其制备方法
CN102526266A (zh) * 2012-03-16 2012-07-04 陕西步长制药有限公司 一种治疗阴道炎的中药制剂及其制备方法
CN102552472A (zh) * 2012-03-16 2012-07-11 陕西步长制药有限公司 一种治疗阴道炎的中药制剂及其制备方法
CN102552468A (zh) * 2011-12-28 2012-07-11 蚌埠丰原涂山制药有限公司 一种治疗高血脂的中药组合物
CN105287967A (zh) * 2015-10-30 2016-02-03 重庆市洪欣食用菌有限公司 治疗高血压的中药组合物及其草药汤剂的制备方法
CN106924470A (zh) * 2017-03-27 2017-07-07 成都海青生物科技有限公司 一种用于治疗高脂血症的丸剂药物及其制备方法
CN107854580A (zh) * 2017-12-22 2018-03-30 裴虎雷 一种降脂的中药组合物及其制备方法
CN108324752A (zh) * 2018-03-20 2018-07-27 楚雄医药高等专科学校 一种三花茯苓茶片及其制备方法与饮用方法
CN112457428A (zh) * 2020-12-25 2021-03-09 大理大学 野生云南山楂多糖的制备与降脂和抗氧化应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1101846A (zh) * 1993-10-20 1995-04-26 王印坤 抗凝降脂的心脑血管疾病治疗中药
CN1395950A (zh) * 2002-07-24 2003-02-12 漆木生 降压益寿茶及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1101846A (zh) * 1993-10-20 1995-04-26 王印坤 抗凝降脂的心脑血管疾病治疗中药
CN1395950A (zh) * 2002-07-24 2003-02-12 漆木生 降压益寿茶及其制备方法

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552468A (zh) * 2011-12-28 2012-07-11 蚌埠丰原涂山制药有限公司 一种治疗高血脂的中药组合物
CN102526276A (zh) * 2012-01-11 2012-07-04 张继述 一种降压药物组合物及其制备方法
CN102526266A (zh) * 2012-03-16 2012-07-04 陕西步长制药有限公司 一种治疗阴道炎的中药制剂及其制备方法
CN102552472A (zh) * 2012-03-16 2012-07-11 陕西步长制药有限公司 一种治疗阴道炎的中药制剂及其制备方法
CN102552472B (zh) * 2012-03-16 2013-07-17 陕西步长高新制药有限公司 一种治疗阴道炎的中药制剂及其制备方法
CN105287967A (zh) * 2015-10-30 2016-02-03 重庆市洪欣食用菌有限公司 治疗高血压的中药组合物及其草药汤剂的制备方法
CN106924470A (zh) * 2017-03-27 2017-07-07 成都海青生物科技有限公司 一种用于治疗高脂血症的丸剂药物及其制备方法
CN107854580A (zh) * 2017-12-22 2018-03-30 裴虎雷 一种降脂的中药组合物及其制备方法
CN108324752A (zh) * 2018-03-20 2018-07-27 楚雄医药高等专科学校 一种三花茯苓茶片及其制备方法与饮用方法
CN112457428A (zh) * 2020-12-25 2021-03-09 大理大学 野生云南山楂多糖的制备与降脂和抗氧化应用

Similar Documents

Publication Publication Date Title
WO2006081739A1 (fr) Composition servant à traiter ou à prévenir l'hyperlipémie, l'hypertension ou l'infiltration lipidique hépatique
TWI380823B (zh) 脂聯素（Ａｄｉｐｏｎｅｃｔｉｎ）濃度上升劑
WO2012034498A1 (fr) Produit d'aliment diététique fonctionnel qui améliore l'immunité des organes
US7846484B2 (en) Composition comprising Hovenia dulcis thunb. extract, Lindera obtusiloba blume extract, or herbal mixture extract thereof
CN108837036A (zh) 一种降脂降压、防治心脑血管疾病的制剂及其制备方法
CN102697982B (zh) 一种具有辅助降血脂功能的组合物及其制备方法
KR101729003B1 (ko) 황칠 추출물 또는 황칠액 발효대사체를 포함하는 통풍 예방 또는 치료용 조성물
CN102188486B (zh) 一种防治脂肪肝的药物组合物及其制备方法
CN101484001A (zh) 蒽二酮化合物
WO2005115422A2 (fr) Compositions contenant un extrait de feuilles d'avocat visant a faire baisser les taux de cholesterol
CN109157584B (zh) 一种具有辅助降血脂功能的组合物及其制备方法和应用
KR20140108104A (ko) 한인진 및 울금의 복합추출물을 유효성분으로 포함하는 비만 관련 질환의 예방, 억제 또는 치료용 조성물
WO2014134833A1 (fr) Composition comestible, son procédé de préparation, et produit alimentaire comprenant la composition
KR100416650B1 (ko) 둥굴레 추출물과 그를 함유한 혈장 지질 및 혈당 강하용조성물
KR100551718B1 (ko) 지방산 합성효소의 활성을 억제할 수 있는 비만 억제용조성물
KR20040043707A (ko) 인진쑥, 애엽, 유근피, 적양, 오가피, 대두 lph펩타이드, 백석목, 메밀을 주성분으로 함유하는 숙취제거, 간염, 간암 치료의 의약 조성물
JP2618286B2 (ja) 降圧酵母製剤及びその製造法
CN109999076A (zh) 一种调节胆固醇逆转运的中药组合物及其应用
CN100358553C (zh) 一种具有降脂减肥作用的中药组合物及制备方法
CN104013695B (zh) 一种海棠果提取物的应用
KR100573591B1 (ko) 비만치료ㆍ억제용 맥문동 추출물
CN112022977B (zh) 治疗高血压的中药组合物及其中药制剂和应用
JP5452536B2 (ja) ヒト血清コレステロール低下作用を有する食品及びヒト高コレステロール血症又はヒト動脈硬化予防又は治療剤
TWI440465B (zh) 用以降血脂的中草藥萃取混合物及其醫藥組合物
KR100573590B1 (ko) 비만치료ㆍ억제용 생약 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06705504

Country of ref document: EP

Kind code of ref document: A1